Summit Corporation plc  

(Public, LON:SUMM)   Watch this stock  
Find more results for SUMM
+0.12 (1.36%)
Real-time:   12:25PM GMT+1
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 8.75 - 9.15
52 week 3.79 - 20.25
Open 9.00
Vol / Avg. 299,032.00/4.40M
Mkt cap 74.92M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 821.23M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Jul '13) 2013
Net profit margin -424.40% -232.91%
Operating margin -473.61% -252.32%
EBITD margin - -190.79%
Return on average assets -76.94% -102.14%
Return on average equity -105.29% -160.74%
Employees 27 -
CDP Score - -


85b Park Drive,Milton Park
United Kingdom - Map
+44-1235-443939 (Phone)
+44-1235-436237 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Summit Corporation plc (Summit) is a drug discovery company. The Company is engaged in developing drug candidates to treat areas of unmet medical need. The Company focuses on advancing three drug programmes targeting Duchenne Muscular Dystrophy, C. difficile infection and Alzheimer�s disease and other tauopathies. The Company�s programmes include SMT 19969, SMT C1100, SMT C2100, SMT 14224, SMT 15000, SMT D001 (Sialorrhoea), SMT D002 (Seborrhoea), Glaucoma / AMD and Tuberculosis Programme. Summit also has Seglin technology, a chemistry based drug discovery platform. The Company�s subsidiaries include Summit (Oxford) Limited, Summit (Wales) Limited, Summit (Cambridge) Limited, Summit Discovery 1 Limited and Summit Corporation Employee Benefit Trust Company Limited.

Officers and directors

Glyn Edwards Chief Executive Officer, Executive Director
Age: 57
Raymond J. Spencer Chief Financial Officer, Company Secretary
Frank Murdoch Armstrong Non-Executive Chairman of the Board
Age: 56
James Mellon Non-Executive Director
Barry J. Price Ph.D. Non-Executive Director
Age: 69